Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
MarketBeat: Week in Review 11/21 - 11/25
THE BEST BLACK FRIDAY DEAL YET (Ad)
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
Inflation hovers over shoppers seeking deals on Black Friday
THE BEST BLACK FRIDAY DEAL YET (Ad)
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
US FCC bans sales, import of Chinese tech from Huawei, ZTE
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Court revives wrongful death claim in Ohio Walmart shooting
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
MarketBeat: Week in Review 11/21 - 11/25
THE BEST BLACK FRIDAY DEAL YET (Ad)
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
Inflation hovers over shoppers seeking deals on Black Friday
THE BEST BLACK FRIDAY DEAL YET (Ad)
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
US FCC bans sales, import of Chinese tech from Huawei, ZTE
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Court revives wrongful death claim in Ohio Walmart shooting
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
MarketBeat: Week in Review 11/21 - 11/25
THE BEST BLACK FRIDAY DEAL YET (Ad)
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
Inflation hovers over shoppers seeking deals on Black Friday
THE BEST BLACK FRIDAY DEAL YET (Ad)
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
US FCC bans sales, import of Chinese tech from Huawei, ZTE
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Court revives wrongful death claim in Ohio Walmart shooting
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
MarketBeat: Week in Review 11/21 - 11/25
THE BEST BLACK FRIDAY DEAL YET (Ad)
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
Inflation hovers over shoppers seeking deals on Black Friday
THE BEST BLACK FRIDAY DEAL YET (Ad)
Macao awards casino licenses to MGM, Sands, Wynn, 3 others
US FCC bans sales, import of Chinese tech from Huawei, ZTE
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Court revives wrongful death claim in Ohio Walmart shooting
NYSE:ABBV

AbbVie - ABBV Stock Forecast, Price & News

$159.62
+0.23 (+0.14%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$159.24
$160.75
50-Day Range
$134.21
$159.79
52-Week Range
$115.10
$175.91
Volume
1.66 million shs
Average Volume
5.58 million shs
Market Capitalization
$282.28 billion
P/E Ratio
21.31
Dividend Yield
3.54%
Price Target
$158.56

AbbVie MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
0.7% Downside
$158.56 Price Target
Short Interest
Healthy
0.78% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.32mentions of AbbVie in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-18.49%
From $14.01 to $11.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

99th out of 1,044 stocks

Pharmaceutical Preparations Industry

37th out of 508 stocks

ABBV stock logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

MarketBeat: Week in Review 11/14 – 11/18 (ABBV)
This week, investors digested negative news from the retail sector and the Fed and next week's abbreviated trading week won't bring much new news.
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
MarketBeat: Week in Review 10/31-11/4 (ABBV)
You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week
Why is AbbVie Stock Falling, but Still Good Long-Term?
Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock.
Why is AbbVie Stock Dropping, but Still Good Long-Term?
Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock.
Better Dividend Stock: AbbVie or Viatris?
THE BEST BLACK FRIDAY DEAL YET
This Black Friday, you can save 95% off of a 1-year membership to Brad Thomas’s Intelligent Income Investor. This service is geared toward helping you collect the safest dividend income in the market. It all starts with Brad’s “SWAN” portfolio, of the 10 best companies to own through any market.
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease
AbbVie Sees Unusually High Options Volume (NYSE:ABBV)
AbbVie Boosts Its Dividend: Is the Dividend King a Buy?
AbbVie: Paid To Wait
AbbVie (NYSE:ABBV) Now Covered by Analysts at Credit Suisse Group
AbbVie (NYSE:ABBV) Stock Price Up 2.2%
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 11/15 Dividend
10/13/2022
Last Earnings
10/28/2022
Dividend Payable
11/15/2022
Today
11/26/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/01/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$158.56
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
-0.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
15 Analysts

Profitability

Net Income
$11.54 billion
Pretax Margin
25.57%

Debt

Sales & Book Value

Annual Sales
$56.20 billion
Cash Flow
$17.70 per share
Book Value
$9.06 per share

Miscellaneous

Outstanding Shares
1,768,480,000
Free Float
1,767,065,000
Market Cap
$282.28 billion
Optionable
Optionable
Beta
0.69

Social Links


Key Executives

  • Mr. Richard A. GonzalezMr. Richard A. Gonzalez (Age 68)
    Chairman & CEO
    Comp: $7.42M
  • Mr. Robert A. MichaelMr. Robert A. Michael (Age 52)
    Vice Chairman & Pres
    Comp: $3.82M
  • Ms. Laura J. SchumacherMs. Laura J. Schumacher (Age 59)
    Vice Chairman of External Affairs & Chief Legal Officer
    Comp: $4.18M
  • Mr. Jeffrey Ryan StewartMr. Jeffrey Ryan Stewart (Age 53)
    Exec. VP & Chief Commercial Officer
    Comp: $3.25M
  • Mr. Scott T. ReentsMr. Scott T. Reents (Age 55)
    Sr. VP & CFO
  • Dr. Azita Saleki-Gerhardt Ph.D.Dr. Azita Saleki-Gerhardt Ph.D. (Age 59)
    Exec. VP of Operations
  • Dr. Thomas J. Hudson (Age 60)
    Sr. VP of R&D and Chief Scientific Officer
  • Ms. Elizabeth Shea
    VP of Investor Relations
  • Mr. Perry C. Siatis
    Exec. VP, Gen. Counsel & Sec.
  • Mr. Timothy J. RichmondMr. Timothy J. Richmond (Age 56)
    Exec. VP & Chief HR Officer













ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price forecast for 2023?

15 equities research analysts have issued 1 year price objectives for AbbVie's shares. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they predict the company's share price to reach $158.56 in the next twelve months. This suggests that the stock has a possible downside of 0.7%.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2022?

AbbVie's stock was trading at $135.40 at the beginning of 2022. Since then, ABBV stock has increased by 17.9% and is now trading at $159.62.
View the best growth stocks for 2022 here
.

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in October. As of October 15th, there was short interest totaling 14,000,000 shares, an increase of 5.3% from the September 30th total of 13,290,000 shares. Based on an average trading volume of 5,420,000 shares, the short-interest ratio is presently 2.6 days.
View AbbVie's Short Interest
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our ABBV earnings forecast
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Friday, October, 28th. The company reported $3.66 earnings per share for the quarter, beating analysts' consensus estimates of $3.57 by $0.09. The business had revenue of $14.81 billion for the quarter, compared to analysts' expectations of $14.95 billion. AbbVie had a trailing twelve-month return on equity of 155.88% and a net margin of 23.19%. The company's revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter last year, the business posted $3.33 earnings per share.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, October 28th. Shareholders of record on Friday, January 13th will be given a dividend of $1.48 per share on Wednesday, February 15th. This represents a $5.92 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date is Thursday, January 12th. This is a boost from the stock's previous quarterly dividend of $1.41.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.54%. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 75.30%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 49.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its fourth quarter 2022 earnings guidance on Sunday, November, 6th. The company provided earnings per share (EPS) guidance of $3.65-$3.69 for the period, compared to the consensus EPS estimate of $3.75. The company issued revenue guidance of $15.20 billion-$15.20 billion, compared to the consensus revenue estimate of $15.78 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?
What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.82%), BlackRock Inc. (7.52%), State Street Corp (4.38%), Price T Rowe Associates Inc. MD (1.39%), Bank of New York Mellon Corp (1.17%) and Nuveen Asset Management LLC (0.77%). Insiders that own company stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $159.62.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $282.28 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.49 on an earnings per share basis.

How many employees does AbbVie have?

The company employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 11/26/2022 by MarketBeat.com Staff